FIG 1.

Eritoran (E5564) treatment does not affect survival during Sp3 infection. (a) WT C57BL/6J mice were either left untreated (NT) or treated with E5564 (200 μg/mouse i.v.) once daily for 5 consecutive days (days −5 to −1) prior to infection with an ∼LD₄₀ of Sp3 (∼1,500 CFU/mouse i.n.) on day (d) 0. Mice were monitored daily for survival for 14 days post-Sp3 infection. (b) WT C57BL/6J mice were infected with an ∼LD₄₀ of Sp3 (∼1,500 CFU/mouse i.n.) on day 0. Mice were either left untreated or treated with E5564 (200 μg/mouse i.v.) once daily for 5 consecutive days starting on day 2 postinfection (days 2 to 6). Mice were monitored daily for survival for 14 days post-Sp3 infection. Results represent combined data from 2 separate assays (4 to 5 mice/treatment group/experiment).